Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN18107202
ISRCTN18107202
Completed
Not Applicable

Comparative evaluation of Immunogenicity of monovalent type 1 Oral Poliovirus Vaccine (mOPV1) and monovalent type 3 Oral Poliovirus Vaccine (mOPV3) versus trivalent Oral Poliovirus Vaccine (tOPV): a randomised double-blind controlled trial in South Africa

World Health Organization (WHO) (Switzerland)0 sites800 target enrollmentNovember 15, 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPoliomyelitisInfections and Infestations

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Poliomyelitis
Sponsor
World Health Organization (WHO) (Switzerland)
Enrollment
800
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 15, 2007
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
World Health Organization (WHO) (Switzerland)

Eligibility Criteria

Inclusion Criteria

  • •1\. Healthy infants (birth weight greater than or equal to 2\.5 kg and Apgar score greater than or equal to 9 at 5 minutes) born at study sites
  • •2\. Residing less than or equal to 50 km from study sites
  • •3\. Family is not planning on travel during the study period (birth to 1 month)

Exclusion Criteria

  • •1\. High risk newborns
  • •2\. Other newborns requiring hospitalisation
  • •3\. Birthweight less than 2\.5 kg
  • •4\. Apgar score less than 9 at 5 minutes
  • •5\. Infants residing more than 50 km from study sites
  • •6\. Infants whose families are planning to be absent during one month study period
  • •7\. A diagnosis or suspicion of B cell immunodeficiency in participant or immediate family
  • •The study will not collect information on acquired immunodefiency disease or Human Immunodeficiency Virus (HIV) status of mother or study subject.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Comparative evaluation of immunogenicity of monovalent type 1 oral poliovirus vaccine (mOPV1) versus trivalent OPV (tOPV): a randomised double-blind trial set in EgyptPolioInfections and Infestations
ISRCTN76316509World Health Organization (WHO) (Switzerland)600
Completed
Not Applicable
Comparative evaluation of immunogenicity of Monovalent Type 1 Oral Poliovirus Vaccine (mOPV1) versus trivalent OPV (tOPV): a randomised double-blind trial set in India (Panacea Biotec Ltd mOPV1 study)PolioInfections and Infestations
ISRCTN80143849Panacea Biotec Ltd (India)600
Not yet recruiting
Phase 4
Comparative evaluation of immunogenicity of various schedules and delivery options to provide fractional Dose Inactivated Poliovirus Vaccine in routine immunizatio
CTRI/2017/02/007793Panacea Biotec Ltd800
Recruiting
Phase 4
Comparing immune response to oral polio vaccine administered at short intervals with vaccine administered at standard intervals in healthy newborns in PakistapoliomyelitisInfection - Other infectious diseasesPublic Health - Other public health
ACTRN12612000276853WHO800
Withdrawn
Phase 4
A comparison of the immune response to two different oral polio vaccine regimes in PakistaPoliomyelitisPublic Health - EpidemiologyInfection - Other infectious diseasesOral and Gastrointestinal - Normal oral and gastrointestinal development and function
ACTRN12611000824965Department of Paediatrics and Child Health, Aga Khan University800